Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $4
Chardan Capital analyst Matthew Barcus maintains Vincerx Pharma (NASDAQ:VINC) with a Buy and lowers the price target from $11 to $4.
SVB Leerink Maintains Outperform on Vincerx Pharma, Lowers Price Target to $6
SVB Leerink analyst Jonathan Chang maintains Vincerx Pharma (NASDAQ:VINC) with a Outperform and lowers the price target from $19 to $6.
Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $11
Chardan Capital analyst Matthew Barcus maintains Vincerx Pharma (NASDAQ:VINC) with a Buy and lowers the price target from $14 to $11.
SVB Leerink Maintains Outperform on Vincerx Pharma, Lowers Price Target to $19
SVB Leerink analyst Jonathan Chang maintains Vincerx Pharma (NASDAQ:VINC) with a Outperform and lowers the price target from $20 to $19.
Vincerx Pharma Highlights VIP152 Preclinical, Clinical Data In Gynecological Cancers
Vincerx Pharma Inc (NASDAQ: VINC) announced a poster presentation of
Vincerx Pharma Presents Preclinical And Preliminary Clinical Data On PTEFb/CDK9 Inhibitor VIP152 In Gynecologic Malignancies At AACR Annual Meeting 2022
Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation